CD44-engineered mesoporous silica nanoparticles for overcoming multidrug resistance in breast cancer

Applied Surface Science

Volumn 332, Issue , 2015, Pages 308-317

  Wang, Xin ^a   Liu, Ying ^a   Wang, Shouju ^a   Shi, Donghong ^a   Zhou, Xianguang ^b   Wang, Chunyan ^a   Wu, Jiang ^a   Zeng, Zhiyong ^a   Li, Yanjun ^a   Sun, Jing ^a   Wang, Jiandong ^a   Zhang, Longjiang ^a   Teng, Zhaogang ^a   Lu, Guangming ^a  

^a NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Breast cancer; CD44; Mesoporous silica; Multidrug resistance; Nanoparticle; Targeted drug delivery system

Indexed keywords

CELL DEATH; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; GLYCOPROTEINS; MESOPOROUS MATERIALS; MONOCLONAL ANTIBODIES; NANOPARTICLES; SILICA NANOPARTICLES; TUMORS;

BREAST CANCER; CD44; MESOPOROUS SILICA; MULTIDRUG RESISTANCE; TARGETED DRUG DELIVERY SYSTEMS;

TARGETED DRUG DELIVERY;

EID: 84924180008     PISSN: 01694332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apsusc.2015.01.204     Document Type: Article

References (55)

1. C. Desantis, J. Ma, and L. Bryan Breast cancer statistics, 2013 CA Cancer J. Clin. 64 2014 52 62
2. Q. Yin, J. Shen, and Z. Zhang Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor Adv. Drug Deliv. Rev. 65 2013 1699 1715
3. H. Zhang, H. Jiang, and X. Wang Reversion of multidrug resistance in tumor by biocompatible nanomaterials Mini Rev. Med. Chem. 10 2010 737 745
4. I.P. Huang, S.P. Sun, and S.H. Cheng Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance Mol. Cancer Ther. 10 2011 761 769
5. T. Nabekura Overcoming multidrug resistance in human cancer cells by natural compounds Toxins (Basel) 2 2010 1207 1224
6. S. Giri, B.G. Trewyn, and V.S. Lin Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems Nanomedicine (Lond) 2 2007 99 111
7. F. Tang, L. Li, and D. Chen Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery Adv. Mater. 24 2012 1504 1534
8. I.I. Slowing, J.L. Vivero-Escoto, and C.W. Wu Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers Adv. Drug Deliv. Rev. 60 2008 1278 1288
9. M. Vallet-Regi, F. Balas, and D. Arcos Mesoporous materials for drug delivery Angew. Chem. Int. Ed. Engl. 46 2007 7548 7558
10. X. Wang, Z.G. Teng, and X.Y. Huang [Mesoporous silica nanoparticles for cancer theranostic drug delivery] Yao xue xue bao [Acta Pharm. Sin.] 48 2013 8 13
11. M. Liu, L.A. Hou, and B. Xi Synthesis, characterization, and mercury adsorption properties of hybrid mesoporous aluminosilicate sieve prepared with fly ash Appl. Surf. Sci. 273 2013 706 716
12. Q. He, Y. Gao, and L. Zhang A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance Biomaterials 32 2011 7711 7720
13. Q. He, and J. Shi MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition Adv. Mater. 26 2014 391 411
14. Y. Gao, Y. Chen, and X. Ji Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles ACS Nano 5 2011 9788 9798
15. L. Li, X. Huang, and T. Liu Overcoming multidrug resistance with mesoporous silica nanorods as nanocarrier of doxorubicin J. Nanosci. Nanotechnol. 12 2012 4458 4466
16. C.H. Lee, S.H. Cheng, and I.P. Huang Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics Angew. Chem. Int. Ed. Engl. 49 2010 8214 8219
17. A.M. Chen, M. Zhang, and D. Wei Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells Small (Weinheim an der Bergstrasse, Germany) 5 2009 2673 2677
18. C.E. Ashley, E.C. Carnes, and G.K. Phillips The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers Nat. Mater. 10 2011 389 397
19. L. Fiandra, S. Mazzucchelli, and C. De Palma Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands ACS Nano 7 2013 6092 6102
20. Y. Cheng, L. Tao, and J. Xu CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients Mol. Carcinog. 53 2014 686 697
21. L.Y. Bourguignon, C.C. Spevak, and G. Wong Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells J. Biol. Chem. 284 2009 26533 26546
22. A.M. Calcagno, C.D. Salcido, and J.P. Gillet Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics J. Natl. Cancer Inst. 102 2010 1637 1652
23. J.W. Cain, R.S. Hauptschein, and J.K. Stewart Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology Mol. Cancer Res. 9 2011 637 647
24. D. Wang, J. Huang, and X. Wang The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel Biomaterials 34 2013 7662 7673
25. L.Y. Bourguignon, K. Peyrollier, and W. Xia Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells J. Biol. Chem. 283 2008 17635 17651
26. K.E. Miletti-Gonzalez, S. Chen, and N. Muthukumaran The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer Cancer Res. 65 2005 6660 6667
27. S. Misra, S. Ghatak, and B.P. Toole Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2 J. Biol. Chem. 280 2005 20310 20315
28. Y.R. Du, Y. Chen, and Y. Gao Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with stemness from human ovarian cancer Int. J. Gynecol. Cancer 23 2013 1367 1375
29. Z. Gadhoum, M.P. Leibovitch, and J. Qi CD44: a new means to inhibit acute myeloid leukemia cell proliferation via p27Kip1 Blood 103 2004 1059 1068
30. M. Yu, S. Jambhrunkar, and P. Thorn Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells Nanoscale 5 2013 178 183
31. Q. He, M. Ma, and C. Wei Mesoporous carbon@silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging Biomaterials 33 2012 4392 4402
32. M. Gary-Bobo, D. Brevet, and N. Benkirane-Jessel Hyaluronic acid-functionalized mesoporous silica nanoparticles for efficient photodynamic therapy of cancer cells Photodiagnosis Photodyn. Ther. 9 2012 256 260
33. M. Yu, L. Zhou, and J. Zhang A simple approach to prepare monodisperse mesoporous silica nanospheres with adjustable sizes J. Colloid Interface Sci. 376 2012 67 75
34. S.M. Lee, H.J. Kim, and S.Y. Kim Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer Biomaterials 35 2014 2272 2282
35. H. Wen, J. Guo, and B. Chang pH-responsive composite microspheres based on magnetic mesoporous silica nanoparticle for drug delivery Eur. J. Pharm. Biopharm. 84 2013 91 98
36. X. Wang, Z.G. Teng, and H.Y. Wang Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system Int. J. Clin. Exp. Pathol. 7 2014 1337 1347
37. A. Monks, D. Scudiero, and P. Skehan Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Natl. Cancer Inst. 83 1991 757 766
38. T. Lei, S. Srinivasan, and Y. Tang Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms Nanomedicine 7 2011 324 332
39. F. Corsi, L. Fiandra, and C. De Palma HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice ACS Nano 5 2011 6383 6393
40. H. Meng, M. Liong, and T. Xia Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line ACS Nano 4 2010 4539 4550
41. J.M. Rosenholm, and M. Linden Towards establishing structure-activity relationships for mesoporous silica in drug delivery applications J. Control. Release 128 2008 157 164
42. J. Shen, Q. He, and Y. Gao Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism Nanoscale 3 2011 4314 4322
43. L. Wang, W. Su, and Z. Liu CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma Biomaterials 33 2012 5107 5114
44. W. Feng, W. Nie, and C. He Effect of pH-responsive alginate/chitosan multilayers coating on delivery efficiency, cellular uptake and biodistribution of mesoporous silica nanoparticles based nanocarriers ACS Appl. Mater Interfaces 6 2014 8447 8460
45. M. de la Torre, P. Heldin, and J. Bergh Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers Anticancer Res. 15 1995 2791 2795
46. Y.L. Lo, K.H. Sung, and C.C. Chiu Chemically conjugating polyethylenimine with chondroitin sulfate to promote CD44-mediated endocytosis for gene delivery Mol. Pharm. 10 2013 664 676
47. A.A. Bhirde, B.V. Chikkaveeraiah, and A. Srivatsan Targeted therapeutic nanotubes influence the viscoelasticity of cancer cells to overcome drug resistance ACS Nano 8 2014 4177 4189
48. Z. Gao, L. Zhang, and Y. Sun Nanotechnology applied to overcome tumor drug resistance J. Control. Release 162 2012 45 55
49. G. Liu, H. Shen, and J. Mao Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations ACS Appl. Mater Interfaces 5 2013 6909 6914
50. M. Schindler, S. Grabski, and E. Hoff Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr) Biochemistry 35 1996 2811 2817
51. L. Qiu, C. Zheng, and Q. Zhao Mechanisms of drug resistance reversal in Dox-resistant MCF-7 cells by pH-responsive amphiphilic polyphosphazene containing diisopropylamino side groups Mol. Pharm. 9 2012 1109 1117
52. J.L. Vivero-Escoto, I.I. Slowing, and B.G. Trewyn Mesoporous silica nanoparticles for intracellular controlled drug delivery Small (Weinheim an der Bergstrasse, Germany) 6 2010 1952 1967
53. K.Y. Choi, H. Chung, and K.H. Min Self-assembled hyaluronic acid nanoparticles for active tumor targeting Biomaterials 31 2010 106 114
54. H.J. Cho, I.S. Yoon, and H.Y. Yoon Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin Biomaterials 33 2012 1190 1200
55. H.Y. Yoon, H. Koo, and K.Y. Choi Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy Biomaterials 33 2012 3980 3989